Abstract
This article provides an overview of a recent 1-day symposium on the current status and the future prospects for small-molecule therapeutics in oncology. Presentations included aspects of kinase inhibition, the targeting of G-quadruplexes, oxygen sensing as a therapeutic target and sulfatase inhibitors for hormone-dependent breast cancer.
Financial & competing interests disclosure
Tatiana McHardy has worked on collaborative projects with Sareum and Astex Therapeutics. Keith Jones has worked on collaborative projects with AstraZeneca and Antisoma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.